SAM HAWKINS: Open Payments
NPI 1912695487 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,012 in 117 payments from 17 companies in 2025. Trend: 2023 $916 · 2024 $1,871 · 2025 $3,012
Food & beverage: $3,012
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $490 |
| Neurocrine BioSciences, Inc. | 9 | $474 |
| ABBVIE INC. | 11 | $390 |
| Alkermes, Inc. | 10 | $257 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $240 |
| Vanda Pharmaceuticals Inc. | 8 | $232 |
| Janssen Pharmaceuticals, Inc | 5 | $115 |
| E.R. Squibb & Sons, L.L.C. | 5 | $108 |
| Almatica Pharma LLC | 6 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $98 |
Products named: REXULTI, INGREZZA, VRAYLAR, ARISTADA, CAPLYTA, FANAPT, COBENFY, LOREEV XR.
Industry payments across NV — which companies pay providers there.
